Independent Advisory Committee Recommends Continuation Of Phase III Oral Calcitonin Studies For Osteoporosis And Osteoarthritis

Unigene Laboratories, Inc. (OTCBB: UGNE) announced that an independent Data Monitoring Committee (DMC) has recommended that Novartis and its partner Nordic Bioscience proceed as planned with their ongoing oral calcitonin Phase III studies for osteoporosis and osteoarthritis…

source : www.medicalnewstoday.com

Related News:

• Hospira Begins Phase I U.S. Clinical Trial Of Biosimilar Erythropoietin In Renal Patients
• iCo Therapeutics Inc. Receives Health Canada Clearance To Conduct Phase II DME Trial With iCo-007
• NPS Pharmaceuticals Announces Completion Of Patient Randomization In Phase 3 STEPS Study Of GATTEX(R) In Short Bowel Syndrome
• Tarsa Therapeutics Advances Phase III ORACAL Trial Of Its Oral Calcitonin For The Treatment Of Postmenopausal Osteoporosis
• KAI Pharmaceuticals Announces Phase 1 Results Of KAI-4169 For The Treatment Of Secondary Hyperparathyroidism (SHPT)
• ThromboGenics Announces Publication Of Positive Microplasmin Phase II Data In The Journal Retina
• Nitric BioTherapeutics Initiates Phase II Onychomycosis Study
• ThromboGenics To Present Results Of Second Phase III Trial Of Microplasmin At The 28th Annual Meeting Of The American Society Of Retina Specialists
• Sylentis Completes Phase I Trial With SYL040012 To Treat Elevated Intraocular Pressure And Glaucoma
• Sepracor Reports Preliminary Results From A Second Phase III Study For OMNARIS(R) HFA Nasal Aerosol In Seasonal Allergic Rhinitis

Details :
Submited at Sunday, December 13th, 2009 at 7:00 am on Orthopaedic by sofia
Comment RSS 2.0 - leave a comment - trackback